Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
IDIX's Cash to Debt is ranked higher than
84% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. IDIX: No Debt )
IDIX' s 10-Year Cash to Debt Range
Min: 2.47   Max: No Debt
Current: No Debt

Equity to Asset 0.77
IDIX's Equity to Asset is ranked higher than
79% of the 1113 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. IDIX: 0.77 )
IDIX' s 10-Year Equity to Asset Range
Min: -0.74   Max: 0.88
Current: 0.77

-0.74
0.88
Interest Coverage No Debt
IDIX's Interest Coverage is ranked higher than
78% of the 680 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IDIX: No Debt )
IDIX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 41.37
M-Score: 67.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 550.02
IDIX's Operating margin (%) is ranked higher than
100% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. IDIX: 550.02 )
IDIX' s 10-Year Operating margin (%) Range
Min: -26379.53   Max: -8.59
Current: 550.02

-26379.53
-8.59
Net-margin (%) 545.06
IDIX's Net-margin (%) is ranked higher than
99% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. IDIX: 545.06 )
IDIX' s 10-Year Net-margin (%) Range
Min: -26073.99   Max: -6.55
Current: 545.06

-26073.99
-6.55
ROE (%) -109.36
IDIX's ROE (%) is ranked higher than
55% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. IDIX: -109.36 )
IDIX' s 10-Year ROE (%) Range
Min: -5602   Max: -15.36
Current: -109.36

-5602
-15.36
ROA (%) -86.85
IDIX's ROA (%) is ranked higher than
54% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. IDIX: -86.85 )
IDIX' s 10-Year ROA (%) Range
Min: -627.45   Max: -4.91
Current: -86.85

-627.45
-4.91
ROC (Joel Greenblatt) (%) -5826.62
IDIX's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. IDIX: -5826.62 )
IDIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5324.09   Max: -150.73
Current: -5826.62

-5324.09
-150.73
Revenue Growth (3Y)(%) -100.00
IDIX's Revenue Growth (3Y)(%) is ranked higher than
53% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. IDIX: -100.00 )
IDIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 235.2
Current: -100

-100
235.2
EBITDA Growth (3Y)(%) 3.50
IDIX's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. IDIX: 3.50 )
IDIX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -69.4   Max: 105.7
Current: 3.5

-69.4
105.7
EPS Growth (3Y)(%) 1.50
IDIX's EPS Growth (3Y)(%) is ranked higher than
79% of the 824 Companies
in the Global Biotechnology industry.

( Industry Median: -4.80 vs. IDIX: 1.50 )
IDIX' s 10-Year EPS Growth (3Y)(%) Range
Min: -77.4   Max: 114
Current: 1.5

-77.4
114
» IDIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

IDIX Guru Trades in Q4 2013

Steven Cohen 13,900 sh (New)
Jeremy Grantham 56,100 sh (+159.72%)
Seth Klarman 36,910,868 sh (+24.42%)
Seth Klarman 36,910,868 sh (+37.90%)
Chuck Royce 665,980 sh (-9.51%)
» More
Q1 2014

IDIX Guru Trades in Q1 2014

Steven Cohen 96,000 sh (+590.65%)
Seth Klarman 53,331,109 sh (+44.49%)
Seth Klarman 53,331,109 sh (unchged)
Jeremy Grantham Sold Out
Chuck Royce 534,316 sh (-19.77%)
» More
Q2 2014

IDIX Guru Trades in Q2 2014

Prem Watsa 50,400 sh (New)
Mario Gabelli 142,184 sh (New)
Seth Klarman 53,331,109 sh (unchged)
Chuck Royce Sold Out
» More
Q3 2014

IDIX Guru Trades in Q3 2014

Seth Klarman Sold Out
Mario Gabelli Sold Out
Prem Watsa Sold Out
Seth Klarman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IDIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Idenix Pharmaceuticals Inc

Seth Klarman Is Top-Performing Guru for First Half 2014
After making a $1 billion gain on Idenix Pharmaceuticals Inc. (IDIX) and his stock picks of the past six months on average gaining 60.8% in the first half of the year compared to about 6% for the S&P 500, Seth Karman resoundingly leads GuruFocus’ scoreboard. Read more...

Ratios

vs
industry
vs
history
P/B 24.26
IDIX's P/B is ranked lower than
53% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. IDIX: 24.26 )
IDIX' s 10-Year P/B Range
Min: 1.28   Max: 74.22
Current: 24.26

1.28
74.22
Current Ratio 6.59
IDIX's Current Ratio is ranked higher than
79% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. IDIX: 6.59 )
IDIX' s 10-Year Current Ratio Range
Min: 1.75   Max: 17.46
Current: 6.59

1.75
17.46
Quick Ratio 6.59
IDIX's Quick Ratio is ranked higher than
80% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. IDIX: 6.59 )
IDIX' s 10-Year Quick Ratio Range
Min: 1.75   Max: 17.46
Current: 6.59

1.75
17.46
Days Sales Outstanding 1096.56
IDIX's Days Sales Outstanding is ranked higher than
66% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 141.98 vs. IDIX: 1096.56 )
IDIX' s 10-Year Days Sales Outstanding Range
Min: 2   Max: 1096.56
Current: 1096.56

2
1096.56

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -4.60
IDIX's Earnings Yield (Greenblatt) is ranked higher than
73% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. IDIX: -4.60 )
IDIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.6   Max: 1.6
Current: -4.6

-4.6
1.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NO9.Germany,
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's main research and development focus is on the treatment of hepatitis C virus, or HCV. HCV is a cause of liver disease. The Company is currently developing nucleoside/nucleotide polymerase inhibitors and NS5A inhibitors to inhibit HCV replication. The Company has developed a non-nucleoside reverse transcriptase inhibitor, or NNRTI, drug candidate, IDX899, for the treatment of human immunodeficiency virus type-1, or HIV, and acquired immune deficiency syndrome, or AIDS, for use in combination therapy. In 2008, it successfully completed a proof-of-concept clinical trial of IDX899 in treatment-naïve HIV-infected patients. In February 2009, it licensed its NNRTI compounds to GlaxoSmithKline. In collaboration with Novartis, it developed telbivudine (Tyzeka/Sebivo) through commercialization for the treatment of patients with HBV. In October 2006, the FDA approved Tyzeka in the United States and Sebivo was approved in 2007 in more than 50 countries outside the United States, including major Asian countries and several countries included in the European Union. Companies the compete with in the HCV market include Abbott Laboratories, Boehringer Ingelheim International GmbH, F. Hoffman-LaRoche & Co., Johnson & Johnson, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis, Gilead Sciences, Inc., Vertex Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc., and Presidio Pharmaceuticals, Inc. The Company is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposing of hazardous materials and waste products, including certain regulations promulgated by the U.S. Environmental Protection Agency, or EPA.
» More Articles for IDIX

Headlines

Articles On GuruFocus.com
Prem Watsa Buys 4 New Stocks Aug 13 2014 
Seth Klarman Tops Guru Scoreboard for First Half 2014 Jul 05 2014 
The Peril of Being a Copycat Jun 26 2014 
Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
2013 - Mistakes of Commission,Omission & Confusion Feb 12 2014 
Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
Seth Klarman Continues Aggressively Buying Drug Company, Soros Adds Mercury Systems Nov 05 2013 
The Philosophy and Value of Gurufocus Sep 08 2013 
Seth Klarman Buys BP, AIG, Elan Corp, Sells News Corp., Oracle May 14 2013 

More From Other Websites
Activists want 'imminent retirement' of Ariad CEO Feb 20 2015
Merck Snags Cubist, Fighter of Superbugs, for $9.5B Dec 08 2014
Health care M&A leads global deal surge Nov 23 2014
Biotech targets: Cramer's quality candidates Sep 11 2014
UPDATE: Deutsche Bank Initiates Coverage On Merck Aug 27 2014
Achillion Pharmaceuticals Up On Buyout Rumors Aug 18 2014
Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower Aug 05 2014
IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Aug 05 2014
IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 31 2014
IDENIX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Jul 31 2014
Merck, Pfizer Ramping R&D After Q2 Earnings Beat Jul 29 2014
Merck 2Q profit more than doubles Jul 29 2014
Every Which Way But Short Jul 24 2014
[video] Cramer's Stop Trading: Yellen effect Jul 16 2014
A Pre-Earnings Update On Gilead Jul 10 2014
Seth Klarman Is Top-Performing Guru for First Half 2014 Jul 05 2014
A Primer On The Hepatitis C Market Jul 03 2014
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline Jul 03 2014
Idenix (IDIX) is in Overbought Territory: What's Next? Jul 03 2014
What If Legacy Pharmaceutical And Consumer Business Keeps Falling For Merck? Jun 27 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK